
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-11-01-2005
- Volume 17
- Issue 11
FDA commissioner quits
Lester Crawford, FDA's top man, has resigned explaining that it was time to step down — despite only being promoted to commissioner earlier this year.
Lester Crawford, FDA's top man, has resigned explaining that it was time to step down — despite only being promoted to commissioner earlier this year. Crawford's tenure at FDA finished with increasing criticism following problems with products and argued decisions. He now faces an enquiry into his resignation by the US Senate Health Committee.
Some of the problems during the erstwhile commissioner's term have caused embarrassment for FDA, such as the safety problems that caused Vioxx to be pulled off the market; mounting recalls of malfunctioning heart devices; and the indefinite postponement of nonprescription emergency contraception sales.
Crawford's experience in food safety was the reason he was elevated by President George Bush from acting commissioner as a preventative measure against bioterrorism. His place has been taken by former National Cancer Institute director and friend of President Bush, Andrew von Eschenbach.
Articles in this issue
over 20 years ago
More Than Skin Deepover 20 years ago
When Simple Isn't Good Enoughover 20 years ago
Lost in the ATEX Maze?over 20 years ago
Reality Checkover 20 years ago
Why It Pays To Be Cleanover 20 years ago
A Virtual Futureover 20 years ago
Dispelling Cleaning Validation Myths: Part Iover 20 years ago
No flies on me, Biotech to the rescueover 20 years ago
SAFC launches biosciences divisionover 20 years ago
Training the Biomanufacturing WorkforceNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.




